Mustang Bio inc (MBIO) - News Archive

Mustang Bio Inc. recently received Orphan Drug Designation from the U.S. FDA for its innovative MB-101 therapy, which utilizes IL13Ra2-targeted CAR T-cells to combat astrocytomas and glioblastomas. This reflects signifi...

Mustang Bio Regains Nasdaq Compliance Amid Strategic Capital MovesMustang Bio, Inc. (Nasdaq: MBIO), a clinical-stage biopharmaceutical company dedicated to advancing innovative cell therapies for hard-to-treat cancers,...

Turning the Tide: Mustang Bio s Journey through Biopharmaceutical Hurdles to Potential ProsperityIn the rapidly evolving world of biotechnology, Mustang Bio stands as a small but determined player striving to transform...

Mustang Bio Secures Crucial Nasdaq Extension: Navigating Challenges AheadMustang Bio, Inc. (Nasdaq: MBIO), a clinical-stage biopharmaceutical company dedicated to advancing innovative cell therapies for hard-to-treat ca...

In a significant stride towards combating one of the most aggressive forms of brain cancer, Mustang Bio has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its innovative product...

Mustang Bio Leverages Warrant Exercise to Fuel Innovative Cancer Research InitiativesIn a significant development for investors and stakeholders, Mustang Bio, Inc. (Nasdaq: MBIO), a clinical-stage biopharmaceutical comp...

Mustang Bio Raises Funds to Further Research on Revolutionary Cell Therapies for Cancer TreatmentWORCESTER, Mass., June 21, 2024 - Mustang Bio, Inc. (Mustang), a clinical-stage biopharmaceutical company specializing in...

Mustang Bio, Inc. Announces Registered Direct Offering and Private Placement to Advance Cell Therapies for Cancer TreatmentWorcester, Mass. June 20, 2024 Mustang Bio, Inc. (Nasdaq: MBIO) has recently made significant st...

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T TherapyOverall response rate of 90% in co...

Mustang Bio Announces Successful Closing of $4 Million Public Offering with Potential for Additional $12 Million in Gross ProceedsWorcester, Mass. - Mustang Bio, Inc. (Nasdaq: MBIO), a clinical-stage biopharmaceutical c...

Mustang Bio, Inc. Announces Pricing of Public Offering to Advance Cell and Gene TherapiesWorcester, Mass.-based biopharmaceutical company Mustang Bio, Inc. made a significant announcement today regarding a public offeri...

Mustang Bio, a pioneer in cell and gene therapies for life-threatening diseases, recently declared its strategic plan for expanding the CAR T-cell therapy platform into the realm of autoimmune diseases. This divergent a...

Mustang Bio, a clinical-stage biopharmaceutical company focused on developing innovative gene therapies for cancer, recently announced the publication of promising data from a Phase 1 clinical trial evaluating their inv...

In a groundbreaking presentation at the 2023 American Society of Hematology (ASH) Annual Meeting, Mustang Bio showcased the updated Phase 1/2 multicenter clinical data for MB-106. The results highlighted the therapy s f...